Home/Pipeline/TNFR1 Antagonist

TNFR1 Antagonist

Immunology & Inflammation

DiscoveryActive

Key Facts

Indication

Immunology & Inflammation

Phase

Discovery

Status

Active

Company

AI Proteins

About AI Proteins

AI Proteins is an early-stage biotech leveraging a proprietary AI-driven platform to design novel miniprotein therapeutics from scratch. The company's closed-loop engine integrates generative AI design, automated synthesis, and lab validation to rapidly create and optimize drug candidates with desired properties like high stability, low immunogenicity, and precise targeting. With a pipeline targeting over 150 drug targets and a significant partnership with Bristol Myers Squibb, AI Proteins is positioning itself at the forefront of next-generation biologic drug discovery.

View full company profile

Therapeutic Areas

Immunology & Inflammation Oncology Metabolic

Other Immunology & Inflammation Drugs

Drug	Company	Phase	Status
YUSIMRY® (adalimumab-fkjp)	Meitheal Pharmaceuticals	Approved	Active
PS-1001	Paratus Sciences	Pre-clinical	Active
Immunology Collaboration (J&J)	Flexomics	Discovery/Research	Active
IMM-001	RapaFusyn Pharmaceuticals	Preclinical	Active
IMM-002	RapaFusyn Pharmaceuticals	Preclinical	Active
IMM-003	RapaFusyn Pharmaceuticals	Preclinical	Active